Contact CFFC


Clinical Trial Alerts – December 2018

Cystic Fibrosis Foundation distributed the following clinical trial update in December. Click the trial title to get more details.

OPTION: Study of AzurRx MS1819 in people with cystic fibrosis and exocrine pancreatic insufficiency who are 18 years and older

Status: Enrolling

Description: This trial will look at the safety and effectiveness of the drug MS1819 as a pancreatic enzyme replacement therapy.

Age: 18 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 30% or greater

Number of Visits: 10

Length of Participation: 11 weeks link:

Comments are closed.